Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
74.81
+1.33 (1.81%)
At close: May 1, 2026, 4:00 PM EDT
74.80
-0.01 (-0.01%)
After-hours: May 1, 2026, 6:46 PM EDT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $264.03M in the quarter ending December 31, 2025, with 10,461.32% growth. This brings the company's revenue in the last twelve months to $1.09B, up 43,539.20% year-over-year. In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M with 23,258.15% growth.
Revenue (ttm)
$1.09B
Revenue Growth
+43,539.20%
P/S Ratio
9.60
Revenue / Employee
$1,534,432
Employees
711
Market Cap
10.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.68% |
| Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
| Sep 30, 2017 | 31.41M | 31.25M | 19,736.48% |
| Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
| Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
| Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
| Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
| Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
| Sep 30, 2011 | 296.14K | - | - |
| Sep 30, 2010 | - | - | - |
| Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
| Sep 30, 2008 | 1.30M | 95.18K | 7.88% |
| Sep 30, 2007 | 1.21M | 746.74K | 161.88% |
| Sep 30, 2006 | 461.28K | -129.40K | -21.91% |
| Sep 30, 2005 | 590.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Bio-Techne | 1.22B |
| Ionis Pharmaceuticals | 1.06B |
| Madrigal Pharmaceuticals | 958.40M |
| Axsome Therapeutics | 638.50M |
| Cytokinetics | 88.04M |
ARWR News
- 2 days ago - Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) - Business Wire
- 9 days ago - Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe - Business Wire
- 12 days ago - This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. - Barrons
- 12 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Arrowhead Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Business Wire